SCHEMBL6606370

SCHEMBL6606370

CCOc1cc(-c2ccccc2)nn1CCOc1ccc(Br)cc1C#N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.38
PDE3A Q14432 1/20 0.38
HTR2C P28335 1/20 0.36
EIF4EBP1 Q13541 1/20 0.36
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
LMNA P02545 1/20 0.34
ADRB2 P07550 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6618274 0.86 HTR1B (0.42) HTR2CKDM4EALDH1A1HPGDADORA2A
SCHEMBL6616088 0.85 KDM4E (0.45) USP2KDM4ERAB9AALDH1A1HPGD
SCHEMBL6600508 0.85 NSD2 (0.40) ALDH1A1ADORA2AADORA1LMNASMN1; SMN2
SCHEMBL6606028 0.85 MGAM (0.43) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL6602669 0.85 KDM4E (0.45) MAPK1KDM4ENPC1RAB9AALDH1A1
SCHEMBL6601666 0.84 CYP11B1 (0.40) MAPK1KDM4ENPSR1ALDH1A1HPGD
SCHEMBL6601689 0.83 SCN9A (0.38) SCN9APDE3AAAK1
SCHEMBL6603253 0.83 KDM4E (0.41) SCN9AMAPK1KDM4ERAB9AALDH1A1
SCHEMBL6606680 0.82 MAPT (0.37) HTR2CMAPK1KDM4ENPC1RAB9A
SCHEMBL6602524 0.81 ADORA1 (0.40) MAPK1KDM4ENPC1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 SCN9A 4788/4885PDE3A 1791/4885HTR2C 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.